Business
Posting of Annual Report and Notice of AGM
Nuformix plc has announced the posting of its Annual Financial Report for the year ended 30 September 2025 and the Notice of the 2026 Annual General Meeting to shareholders. The company, which focuses on drug repurposing for fibrosis and oncology, has made the full PDF versions of these documents available on its website. The Annual General Meeting is scheduled to take place on 3 March 2026 at 9:30 a.m. at Arch Law, level 2, Huckletree, 8 Bishopsgate, London, EC2N 4BQ. Disclaimer*
About this update from Nuformix Plc
[{"type":"text","content":"\n\n5 February 2026\nNuformix plc\n(\"Nuformix\" or the \"Company\")\nPosting of Annual Report and Notice of Annual General Meeting (\"AGM\")\nNuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual Financial Report for the year ended 30 September 2025 (the \"Annual Financial Report 2025\") and the 2026 Notice of AGM are today being posted to its shareholders.\nA full pdf version of the Annual Financial Report 2025 together with the Notice of AGM is available for download from the Investor Information section on the Company's website: www.nuformix.com.\nThe Annual General Meeting will be held at the offices of Arch Law, level 2, Huckletree, 8 Bishopsgate, London, EC2N 4BQ at 9.30 a.m. on 3 March 2026.\nEnquiries:\n \n\n\n\n\nNuformix plc\n\n\n \n\n\n\n\nDr Dan Gooding, Executive Director\n \n\n\nVia IFC Advisory\n\n\n\n\nCMC Markets\n\n\n \n\n\n\n\nDouglas Crippen\n\n\n+44 (0) 20 3003 8632\n\n\n\n\n \n\n\n \n\n\n\n\nIFC Advisory Limited\n\n\n \n\n\n\n\nTim Metcalfe\nZach Cohen\n\n\n+44 (0) 20 3934 6632\[email protected]\n\n\n\n\n \nAbout Nuformix\nNuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.\nFor more information, please visit www.nuformix.com.\n \n \n\n","length":4800,"tagName":"div"}]